AAV products are purified through an optimized manufacturing process, ideal for in vitro cell culture and in vivo animal studies.
uBriGene’s AAV products are produced with extensive expertise in AAV production and are supported by a comprehensive suite of quality control testing.
AAV products produced using uBriGene’s high yield AAV suspension production cells.
Produced using stream-lined AAV production processes.
Several full/empty testing methods, AUC, TEM, and HPLC
Custom large scale and GMP AAV manufacturing capability
| Product Name | Catalog Number | Description | Titer | Volume/ Vial | Price |
|---|---|---|---|---|---|
| AAV1-luciferase | 1305AAV1-luciferase | AAV1 virus expressing CMV driven luciferase | >1E13 vg/mL | 500 uL | |
| MyoAAV 1A-GFP | 1305MyoAAV 1A-GFP | MyoAAV 1A expressing CAG driven GFP | >1E13 vg/mL | 500 uL | |
| AAV2-CAG-GFP | 1305AAV2-GFP | AAV2 virus expressing CAG driven GFP | >5E12 vg/mL | 500 uL | Request a Quote |
| AAV8-CAG-GFP | 1305AAV8-GFP | AAV8 virus expressing CAG driven GFP | >1E13 vg/mL | 500 uL | |
| AAV9-CAG-GFP | 1305AAV9-GFP | AAV9 virus expressing CAG driven GFP | >1E13 vg/mL | 500 uL |
Note: If you require a different AAV titer or scale, an alternative AAV serotype, or a custom gene of interest, we offer custom AAV production services. Request a Quote.
Request a quoteProduced using AAV suspension cells
Best for in vivo animal studies and in vitro cell culture
As an experienced AAV CDMO provider, uBriGene supports your AAV packaging needs for discovery and preclinical studies with scalable and optimized production processes.
High-quality AAV products are manufactured using uBriGene’s fully validated helper and rep/cap plasmids, along with our proprietary high-yield AAV suspension production cell line. After three-plasmid transient transfection, AAV products are purified through ultracentrifugation or chromatography, depending on the production scale.
AAV titers are determined by qPCR. If additional quality testing is required, we offer a comprehensive suite of AAV testing, including assessments of safety, potency, and the AAV full/empty particle ratio.
uBriGene offers ready-to-use AAV products including AAV1-luciferase, MyoAAV 1A-GFP, AAV2-CAG-GFP, AAV8-CAG-GFP, and AAV9-CAG-GFP, with titers ranging from >5 × 10¹² to >1 × 10¹³ vg/mL depending on the product. Additional AAV serotypes, fluorescent or reporter proteins, and custom genes of interest can be supported through custom AAV production services.
Yes, uBriGene is a leader in AAV CDMO services with extensive experience in AAV production. We have successfully delivered over 50 GMP AAV batches and support both research and GMP-grade AAV manufacturing.
There are various naturally occurring AAV serotypes, each with slight capsid variations and specific tissue and cell tropisms. You can use our different AAV serotype GFP viruses to test your cells and identify the serotype that best transduces your specific cell type.
Adeno-associated virus (AAV) is a viral vector widely used for gene delivery because different AAV capsids can provide distinct tissue and cell tropisms. AAV vectors can deliver genetic material to a range of target cells and support sustained transgene expression, making them widely used in gene therapy research and development. AAV does not normally integrate its vector genome into the host genome, although persistence and expression characteristics depend on the vector design, target cells, and application.
uBriGene supports scalable AAV manufacturing from development through GMP production, with GMP AAV manufacturing capacity ranging from 10 L to 2,000 L. The platform has successfully delivered more than 50 GMP AAV batches.
uBriGene manufactures high-quality AAV vectors using a three-plasmid transient transfection system in a proprietary high-yield suspension cell line. Helper and rep/cap plasmids are fully validated, and AAV particles are purified using ultracentrifugation or chromatography, depending on the scale. This process ensures a high yield of potent, purified AAV vectors.
AAV titers are determined using quantitative PCR (qPCR) to accurately measure genome copies per milliliter (vg/mL). For clients requiring additional quality assurance, we offer a complete suite of testing, including assessments of safety, potency, and the AAV full-to-empty particle ratio, to ensure consistency and performance.
Yes, uBriGene provides custom AAV production services where clients can specify their gene of interest (GOI). This flexibility enables researchers to develop tailored solutions for their specific applications, including gene function studies, disease modeling, and therapeutic gene delivery.
uBriGene ships AAV vectors on dry ice to maintain stability during transit. For long-term storage, AAV particles should be aliquoted and stored at -80°C. Proper storage helps preserve vector integrity and ensures optimal performance in research and therapy applications.
uBriGene provides comprehensive AAV quality testing, including vector titer, identity, purity, potency, safety, and full/empty capsid analysis. Full/empty ratios can be evaluated using orthogonal methods including analytical ultracentrifugation (AUC), transmission electron microscopy (TEM), and HPLC, depending on the product and testing requirements.
uBriGene uses orthogonal analytical methods including analytical ultracentrifugation (AUC), transmission electron microscopy (TEM), and HPLC to characterize AAV full, partial, empty, and aggregate capsids. AUC provides quantitative characterization of the different capsid populations and is used as a preferred method for full/empty ratio analysis.
Yes. uBriGene provides research-grade and GMP-grade AAV helper and Rep/Cap plasmids that have been tested for AAV production performance. The plasmids are available with FDA DMF documentation, and uBriGene has supported clients using these plasmids in AAV programs that obtained IND clearance.
Extensive expertise with a track record of successfully releasing over 60 GMP batches of AAV.
Ready-to-use AAV products
Custom AAV productions
Research and GMP AAV manufacturing
Ask the plasmid DNA expert! With over 300 GMP batches in our track record and our cost-effective platform technology, we can help accelerate your clinical programs.
